Agilus’s Idylla claims to deliver cancer mutation results in just 3 hours

Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology

STRIDE-based regimens show survival momentum in EMERALD-3 liver cancer trial

While overall survival data remain immature, the results pointed to a favourable trend.

AstraZeneca combo therapy shows breakthrough in liver cancer trial

The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival

HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer

ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium

AstraZeneca’s Imfinzi combination shows positive results in phase 3 liver cancer study

About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation

USFDA approves Imjudo in combination with Imfinzi for liver cancer

Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib

SCG Cell Therapy announces HSA clinical trial approval of TCR-T cell therapy for liver cancer

SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer

Imfinzi plus tremelimumab significantly improved overall survival in liver cancer

The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib

AstraZeneca to showcase cancer pipeline push at ASCO 2026

Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies

Novo Nordisk unveils breakthrough MASH data as ‘silent’ liver disease threatens 250 million